Consistent with this concept, anti-inflammatory therapy with the IL-1β monoclonal antibody canakinumab in NSCLC, which is often driven by KRAS mutations, significantly reduced lung cancer incidence and mortality89. Here, KRAS is linked to lung carcinoma.